Callan Capital LLC Reduces Holdings in Illumina, Inc. (NASDAQ:ILMN)

Callan Capital LLC decreased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 21.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,749 shares of the life sciences company’s stock after selling 473 shares during the quarter. Callan Capital LLC’s holdings in Illumina were worth $244,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. abrdn plc boosted its stake in shares of Illumina by 764.9% during the fourth quarter. abrdn plc now owns 339,023 shares of the life sciences company’s stock worth $47,206,000 after buying an additional 299,827 shares during the period. J.P. Morgan Private Wealth Advisors LLC acquired a new stake in Illumina in the third quarter valued at about $29,558,000. International Assets Investment Management LLC lifted its position in Illumina by 210.5% in the fourth quarter. International Assets Investment Management LLC now owns 48,194 shares of the life sciences company’s stock valued at $6,711,000 after purchasing an additional 32,672 shares during the period. Aquila Investment Management LLC increased its holdings in Illumina by 150.0% in the fourth quarter. Aquila Investment Management LLC now owns 25,000 shares of the life sciences company’s stock valued at $3,481,000 after buying an additional 15,000 shares in the last quarter. Finally, Weil Company Inc. increased its holdings in Illumina by 59.2% in the third quarter. Weil Company Inc. now owns 22,963 shares of the life sciences company’s stock valued at $3,152,000 after buying an additional 8,539 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Up 1.0 %

Illumina stock traded up $1.23 during trading on Friday, reaching $122.28. 829,310 shares of the company’s stock were exchanged, compared to its average volume of 1,718,479. The company’s 50-day moving average is $131.51 and its two-hundred day moving average is $127.39. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.29 and a current ratio of 1.66. Illumina, Inc. has a 52-week low of $89.00 and a 52-week high of $213.91. The firm has a market cap of $19.47 billion, a price-to-earnings ratio of -16.66 and a beta of 1.19.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The firm had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same period in the prior year, the company earned $0.14 EPS. The firm’s revenue was up 3.6% on a year-over-year basis. On average, analysts predict that Illumina, Inc. will post 0.91 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Stephens reaffirmed an “overweight” rating and issued a $170.00 target price on shares of Illumina in a report on Wednesday, April 10th. TD Cowen cut shares of Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 target price for the company. in a report on Thursday, January 4th. OTR Global reaffirmed a “mixed” rating on shares of Illumina in a report on Wednesday, March 20th. Royal Bank of Canada reissued an “outperform” rating and set a $253.00 price objective on shares of Illumina in a research note on Tuesday, April 9th. Finally, HSBC cut shares of Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, January 16th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $167.70.

Insider Buying and Selling at Illumina

In other news, CEO Jacob Thaysen acquired 7,330 shares of the firm’s stock in a transaction on Thursday, February 22nd. The stock was bought at an average cost of $135.29 per share, with a total value of $991,675.70. Following the transaction, the chief executive officer now directly owns 14,861 shares in the company, valued at approximately $2,010,544.69. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.17% of the stock is currently owned by corporate insiders.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.